| Literature DB >> 35122675 |
Matheus Vilardo Lóes Moreira1, Ingeborg Maria Langohr2, Marina Rios de Araújo Campos3, Enio Ferreira3, Bárbara Carvalho3, Guilherme Reis Blume4, Fabiano Montiani-Ferreira5, Roselene Ecco1.
Abstract
OBJECTIVE: Gross, histopathological, and immunohistochemical characteristics of uveal melanocytic neoplasms in dogs and cats were investigated. SAMPLES: Thirty-two enucleated globes with uveal melanocytic neoplasms, 27 from dogs and 5 from cats, were examined. PROCEDURES: Morphological characteristics of uveal melanocytic neoplasms in dogs and cats were evaluated with anti-PNL2, anti-Melan-A, anti-Ki-67, anti-caspase-3, and anti-BAP1 immunomarkers. Statistical analysis was performed to compare canine melanocytomas and melanomas.Entities:
Keywords: apoptosis; globe; immunohistochemistry; melanocytoma; melanoma; tumour aggressiveness factors
Mesh:
Substances:
Year: 2022 PMID: 35122675 PMCID: PMC9122463 DOI: 10.1002/vms3.752
Source DB: PubMed Journal: Vet Med Sci ISSN: 2053-1095
Primary antibodies and protocols for immunohistochemistry
| Antibody (catalogue N°) | Manufacturer | Clonality | Concentration | Antigen retrieval | Incubation (h) | Counterstain | Positive control |
|---|---|---|---|---|---|---|---|
| PNL2 (sc‐59306) | Santa Cruz Biotechnology | PNL2 | 1:50 | Citrate (pH 6.0) + moist heat | 16 | Giemsa + haematoxylin | Oral melanoma |
| Melan‐A (IS633) | DAKO | A103 | 1:100 | Citrate (pH 6.0) + pressurized moist heat | 16 | Giemsa + haematoxylin | Oral melanoma |
| BAP1 (sc‐28383) | Santa Cruz Biotechnology | C‐4 | 1:50 | Citrate (pH 6.0) + moist heat | 16 | Giemsa + haematoxylin | Liver and retinal pigment epithelium |
| Ki‐67 (M7240) | DAKO | MIB‐1 | 1:50 | Citrate (pH 6.0) + pressurized moist heat | 16 | Giemsa | Oral melanoma |
| Caspase‐3 (RB‐1197‐P) | NeoMarkers | CPP32 | 1:100 | Citrate (pH 6.0) + pressurized moist heat | 1 | Giemsa + haematoxylin | Murine thymus in involution |
Oral melanoma of previously positive dogs (Wiggans et al., 2016).
Internal control (Koopmans et al., 2014; Wiggans et al., 2016).
Canine oral melanoma with high cell proliferation index.
Clinical‐pathological characteristics of uveal melanocytic neoplasms in 27 dogs
| N° | Melanoma | Melanocytoma | |
|---|---|---|---|
| Age | |||
| 24 | 9.25 (0.97) | 9.71 (0.8) | |
| Breeds, N° (%) | |||
| Crossbreed | 7 | 5 (71) | 2 (29) |
| Pure breeds | 17 | 5 (29) | 12 (71) |
| Sex, N° (%) | |||
| Male | 14 | 4 (29) | 10 (71) |
| Female | 13 | 4 (31) | 9 (69) |
| Anatomic location, N° (%) | |||
| Anterior uvea (iris and ciliary body) | 22 | 5 (23) | 17 (77) |
| Entire uveal tract (iris, ciliary body, and choroid) | 5 | 3 (60) | 2 (40) |
| Cellular morphology, N° (%) | |||
| Epithelioid | 9 | 4 (44) | 5 (56) |
| Fusiform | 2 | 0 (0) | 2 (100) |
| Mixed | 16 | 4 (25) | 12 (75) |
| Tumour characteristics, N°(%) | |||
| Anisocytosis | |||
| Mild | 17 | 2 (12) | 15 (88) |
| Moderate | 5 | 1 (20) | 4 (80) |
| Marked | 5 | 5 (100) | 0 (0) |
| Anisocariosis | |||
| Mild | 17 | 1 (6) | 16 (94) |
| Moderate | 3 | 2(67) | 1 (33) |
| Marked | 5 | 5 (100) | 0 (0) |
| % of neoplastic cells with melanin | |||
| 1%–50% (low pigmentation) | 9 | 7 (78) | 2 (22) |
| 51%–100% (high pigmentation) | 18 | 1 (6) | 17 (94) |
| Melanin concentration | |||
| Mild | 3 | 2 (67) | 1 (33) |
| Moderate | 9 | 5 (56) | 4 (44) |
| Marked | 15 | 1 (7) | 14 (93) |
| Mitotic count, mean (SD) | 14 | 19.13 (5.97) | 1.16 (0.16) |
| Inflammation, N° (%) | |||
| Absent | 10 | 2 (20) | 8 (80) |
| Mild | 16 | 5 (31) | 11 (69) |
| Marked | 1 | 1 (100) | 0 (0) |
| Necrosis, N° (%) | |||
| Absent | 12 | 2 (17) | 10 (83) |
| Mild | 10 | 2 (20) | 8 (80) |
| Marked | 5 | 4 (80) | 1 (20) |
| Glaucoma, N° (%) | |||
| Absent | 3 | 0 (0) | 3 (100) |
| Present | 14 | 5 (36) | 9 (64) |
Abbreviation: N°, number.
Some data were not available or an evaluation was not possible for all eight canine melanomas.
Some data were not available or an evaluation was not possible for all 19 canine melanocytomas.
Three dogs with unknown breed.
Pure breeds included German shepherd, basset hound, boxer, bulldog, dachshund, Labrador retriever, Lhasa apso, miniature pinscher, Rottweiler, standard schnauzer, and Yorkshire terrier.
In one dog, the neoplasm infiltrated the peripheral portion of the choroid.
In 10 dogs, the neoplasm expanded to the peripheral portion of the choroid.
Significant difference (p < 0.05) in exact of fisher or χ 2 test or unpaired t tests.
FIGURE 1Gross images of uveal melanocytic neoplasia in the globes of dogs and cats. (a) Panuveal melanocytoma in an 8‐year‐old male mixed‐breed dog. The markedly pigmented neoplasm fills the anterior and posterior compartments, extensively infiltrates the corneal (arrow) and extraocular region (arrowhead), and causes iridocorneal angle obstruction and posterior lens luxation. (b) Anterior uveal melanoma in a 12‐year‐old female miniature pinscher dog. This markedly pigmented neoplasm, which effaces the anterior compartment, has peripheral choroidal invasion, iridocorneal angle obstruction and retinal detachment (arrowheads). (c) Anterior uveal melanoma in an 8‐year‐old male mixed‐breed dog. This poorly pigmented neoplasm effaces the anterior compartment, with corneal and sclera invasion (arrow) and iridocorneal angle obstruction. (d) Diffuse iris melanoma in a 10‐year‐old male Persian cat. This neoplasm is moderately pigmented, causing diffuse thickening of the iris and ciliary body (arrows)
Clinical‐pathological and immunohistochemical characteristics of uveal melanomas in five cats
| Signalment | Histological characteristics | Immunohistochemical characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Breed/sex/age | Anatomical location | Cell morphology | Cells with melanin | Intracellular melanin concentration | Anisocytosis | Anisocaryosis | Lymphocytic inflammation | Necrosis | Glaucoma | PNL2 | BAP1 |
| Mixed‐breed/male/11 years | Anterior uvea (iris and ciliary body) | Epithelioid | 51%–75% | Marked | Marked | Marked | Absent | Absent | Present | Marked (76%–100%) | Multifocal to coalescing (10%–90%) |
| Persian/male/10 years | Anterior uvea (iris and ciliary body) | Mixed | 26%–50% | Moderate | Marked | Marked | Mild ‐ multifocal | Mild ‐ multifocal | Present | Marked (76%–100%) | Diffuse (> 90%) |
| Persian/female/11 years | Anterior uvea (iris and ciliary body) | Balloon cell | 1%–25% | Mild | Moderate | Moderate | Absent | Absent | Present | Marked (76%–100%) | Diffuse (> 90%) |
| Mixed‐breed/female/4 years | Anterior uvea (iris and ciliary body) | Balloon cell | 26%–50% | Moderate | Marked | Marked | Mild ‐ multifocal | Absent | Absent | Marked (76%–100%) | Multifocal to coalescing (10%–90%) |
| Angora/male/3 years | Anterior uvea (iris and ciliary body) | Signet ring cell | 26%–50% | Mild | Marked | Marked | Mild ‐ multifocal | Marked ‐ multifocal to coalescent | Present | Mild (10%–50%) | Multifocal to coalescing (10%–90%) |
Cats with more than one morphological type (giant multinucleated cells and signet ring cells).
FIGURE 2Histologic characteristics of uveal melanocytic neoplasms in dogs and cats. (a) Spindle cell melanocytoma in a 12‐year‐old female miniature pinscher dog; (b) epithelioid cell melanoma in an 8‐year‐old male mixed‐breed dog; (c) mixed cell melanocytoma in an 8‐year‐old male mixed‐breed dog; (d) balloon cell melanoma in an 11‐year‐old female Persian cat. (Hematoxylin and eosin, 400×)
Immunohistochemical characteristics of uveal melanocytic neoplasms in 27 dogs
| No. | Melanoma | Melanocytoma | |
|---|---|---|---|
| PNL‐2, No (%) | |||
| Absent to minimal (0%–9%) | 3 | 2 (67) | 1 (33) |
| Mild (10%–50%) | 5 | 3 (60) | 2 (40) |
| Moderate (51%–75%) | 5 | 1 (20) | 4 (80) |
| Marked (75%–100%) | 14 | 2 (14) | 12 (86) |
| BAP‐1, No (%) | |||
| Multifocal to coalescing (10%–90%) | 18 | 4 (22) | 14 (78) |
| Diffuse (90%–100%) | 9 | 4 (44) | 5 (56) |
| Ki‐67, mean, (SD) | 8 | 38.3 (12.61) | 6.45 (2.05) |
| Caspase (median) | 15 | 58.4 | 13.9 |
Some data were not available or an evaluation was not possible for all eight canine melanomas.
Some data were not available or an evaluation was not possible for all 19 canine melanocytomas.
significant difference (p < 0.05) in unpaired t test.
significant difference (p < 0.05) in Mann–Whitney test.
FIGURE 3Anti‐PNL2 immunolabelling of uveal melanocytic neoplasms in cats. (a) Diffuse iris melanoma in a 4‐year‐old female mixed‐breed cat, with diffuse and strong labelling in the iris and ciliary body (arrows) (subgross). (b) Higher magnification of the neoplasm in image a demonstrating the cytoplasmic labelling (400×). For all images, the diaminobenzidine (DAB) chromogen (brown) was used, contrasting with the melanin (blue‐green). Counterstaining: Giemsa and haematoxylin
FIGURE 4Anti‐BAP1 immunolabelling of uveal melanocytic neoplasms in dogs and cats. (a) Melanoma in a 12‐year‐old male Rottweiler dog, with multifocal to coalescing nuclear and cytoplasmic labelling. (b) Melanoma with low pigmentation in a 3‐year‐old male Angora cat, with multifocal to coalescing nuclear labelling. For all images, the diaminobenzidine (DAB) chromogen (brown) was used, contrasting with the melanin (blue‐green). Counterstaining: Giemsa and haematoxylin (400×)
FIGURE 5Anti‐Ki‐67 immunolabelling of uveal melanocytic neoplasms in dogs and cats. (a) Melanoma in a 6‐year‐old male Rottweiler dog, with a high proliferation index; (b) melanoma in an 11‐year‐old female Persian cat, with high proliferation index. (a) Counterstaining: haematoxylin; (b) counterstaining: Giemsa. For all images, the diaminobenzidine (DAB) chromogen (brown) was used, and the labelling is nuclear
FIGURE 6Anti‐caspase‐3 immunolabelling of uveal melanocytic neoplasms in dogs and cats. (a) Melanocytoma in a 13‐year‐old female basset hound dog, with a low apoptotic index; (b) melanoma in a 6‐year‐old, male Rottweiler dog, with a high apoptotic index; (c) melanoma in a 4‐year‐old female mixed‐breed cat, with a low apoptotic index; (d) melanoma in a 3‐year‐old male Angora cat, with a high apoptotic index. For all images, the diaminobenzidine (DAB) chromogen (brown) was used, contrasting with the melanin (blue‐green). Counterstaining: Giemsa and haematoxylin (400×)